NeoGenomics has introduced NeoTYPE prognostic panel for detection of mutations in splicing factor 3b subunit 1 (SF3B1) gene of chronic lymphocytic leukemia (CLL) in the US.
The CLL Profile panel also includes assays for IgVH mutation analysis, ZAP-70 expression measured by flow cytometry, and FISH tests targeting abnormalities of certain genes associated with CLL.
In addition to CLL, SF3B1 mutation analysis is used for diagnosing and determining prognosis in patients with myelodysplastic syndrome.
NeoGenomics chairman and CEO Douglas VanOort said, "Our new NeoTYPE Cancer Profile tests are designed to provide physicians with comprehensive information about the biology and potential clinical behavior of specific cancers so patients can be offered the best quality personalized management and therapies that are targeted to their specific cancers."
NeoGenomics research and development chief medical officer and director Maher Albitar said CLL can have different severity depending on the genomic makeup of the leukemic cells.
"Our goal is to provide patients and their treating physicians with the most comprehensive prognostic indicators available so that treatment options and management can be well planned and precisely tailored for each individual patient," Albitar added.
